Patents by Inventor Jeffrey L. Garwin
Jeffrey L. Garwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8486656Abstract: Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.Type: GrantFiled: June 13, 2011Date of Patent: July 16, 2013Assignee: Biomoda, Inc.Inventor: Jeffrey L. Garwin
-
Publication number: 20120149057Abstract: Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.Type: ApplicationFiled: June 13, 2011Publication date: June 14, 2012Applicant: Biomoda, Inc.Inventor: Jeffrey L. Garwin
-
Patent number: 7960138Abstract: Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.Type: GrantFiled: March 2, 2010Date of Patent: June 14, 2011Assignee: Biomoda, Inc.Inventor: Jeffrey L. Garwin
-
Publication number: 20100216169Abstract: Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.Type: ApplicationFiled: March 2, 2010Publication date: August 26, 2010Applicant: BIOMODA, INC.Inventor: Jeffrey L. Garwin
-
Patent number: 7670799Abstract: Presented is a method of solubilizing TCPP, as well as a composition comprising TCPP solubilized by this method.Type: GrantFiled: June 5, 2008Date of Patent: March 2, 2010Assignee: Biomoda, Inc.Inventor: Jeffrey L. Garwin
-
Publication number: 20090004690Abstract: Presented is a method to detect precancerous states in mammalian cell and tissue samples comprising incubating a sample with solubilized 5, 10, 15, 20-tetrakis (carboxyphenyl)porphine (TCPP), measuring TCPP fluorescence in the sample, and categorizing the sample as non-cancerous, precancerous or cancerous based on TCPP fluorescence, as correlated with the respective states of the cells. In conjunction with the method a detection, a novel and more efficient method of solubilizing TCPP is presented, as well as a composition comprising TCPP solubilized by this method.Type: ApplicationFiled: June 5, 2008Publication date: January 1, 2009Applicant: BIOMODA, Inc.Inventor: Jeffrey L. Garwin
-
Patent number: 7384764Abstract: Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; removing unbound TCPP from the sample; c detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients's response to the cancer therapy.Type: GrantFiled: September 2, 2004Date of Patent: June 10, 2008Assignee: BIOMODA, Inc.Inventor: Jeffrey L. Garwin
-
Patent number: 6838248Abstract: Presented is a method to detect precancerous states in mammalian cell and tissue samples comprising incubating a sample with solubilized 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (TCPP), measuring TCPP fluorescence in the sample, and categorizing the sample as non-cancerous, precancerous or cancerous based on TCPP fluorescence, as correlated with the respective states of the cells. In conjunction with the method a detection, a novel and more efficient method of solubilizing TCPP is presented, as well as a composition comprising TCPP solubilized by this method.Type: GrantFiled: November 19, 2001Date of Patent: January 4, 2005Assignee: BioModa, Inc.Inventor: Jeffrey L. Garwin
-
Publication number: 20040030672Abstract: A dynamic health metric reporting system for prospectively collecting data relevant to improve the utility of medical diagnostic technology, where the diagnostic technology produces digital data stored in an electronic database along with demo graphic and treatment data for individual patients.Type: ApplicationFiled: September 9, 2003Publication date: February 12, 2004Inventor: Jeffrey L Garwin
-
Publication number: 20020115121Abstract: Presented is a method to detect precancerous states in mammalian cell and tissue samples comprising incubating a sample with solubilized 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (TCPP), measuring TCPP fluorescence in the sample, and categorizing the sample as non-cancerous, precancerous or cancerous based on TCPP fluorescence, as correlated with the respective states of the cells. In conjunction with the method a detection, a novel and more efficient method of solubilizing TCPP is presented, as well as a composition comprising TCPP solubilized by this method.Type: ApplicationFiled: November 19, 2001Publication date: August 22, 2002Inventor: Jeffrey L. Garwin
-
Patent number: 5612054Abstract: This invention relates to a pharmaceutical composition for treating gastrointestinal distress comprising an effective amount of an antidiarrheal composition, e.g. loperamide, and an antiflatulent effective amount of simethicone and methods of treating gastrointestinal distress comprising administering such pharmaceutical compositions.Type: GrantFiled: April 19, 1995Date of Patent: March 18, 1997Assignee: McNeil-PPC, Inc.Inventor: Jeffrey L. Garwin
-
Patent number: 5272254Abstract: DNA sequences, hybrid DNA sequences, recombinant DNA molecules and processes for producing streptavidin-like polypeptides and for producing fused proteins consisting of a streptavidin-like polypeptide joined end to end with another protein, polypeptide, peptide or amino acid. The DNA sequences, hybrid DNA sequences and recombinant DNA molecules of this invention are characterized in that they include DNA fragments that code for streptavidin-like polypeptides. These DNA sequences, hybrid DNA sequences and recombinant DNA molecules and the hosts transformed with them may be employed in the processes of this invention to produce streptavidin-like polypeptides and fused proteins.Type: GrantFiled: November 27, 1991Date of Patent: December 21, 1993Assignee: Biogen Inc.Inventors: Harry M. Meade, Jeffrey L. Garwin
-
Patent number: 5248505Abstract: This invention relates to a pharmaceutical composition for treating gastrointestinal distress comprising an effective amount of an antidiarrheal composition, e.g. loperamide, and an antiflatulent effective amount of simethicone and methods of treating gastrointestinal distress comprising administering such pharmaceutical compositions.Type: GrantFiled: March 17, 1992Date of Patent: September 28, 1993Assignee: McNeil-PPC, Inc.Inventor: Jeffrey L. Garwin
-
Patent number: 5246717Abstract: Chicken eggs are provided which contain controlled amounts of vitamin E and iodine. No more than about 34% of the fatty acid content of the eggs comprises saturated fatty acid. The eggs may be eaten in the context of a standard low fat diet, without increasing the dieter's serum cholesterol concentration. The eggs are produced by maintaining egg laying chickens on a diet free of animal fat, wherein conventional feed is supplemented with controlled amounts of unsaturated fatty acid, iodine and vitamin E.Type: GrantFiled: October 31, 1991Date of Patent: September 21, 1993Assignee: C. R. Eggs Inc.Inventor: Jeffrey L. Garwin
-
Patent number: 5168049Abstract: DNA sequences, hybrid DNA sequences, recombinant DNA molecules and processes for producing streptavidin-like polypeptides and for producing fused proteins consisting of a streptavidin-like polypeptide joined end to end with another protein, polypeptide, peptide or amino acid. The DNA sequences, hybrid DNA sequences and recombinant DNA molecules of this invention are characterized in that they include DNA fragments that code for streptavidin-like polypeptides. These DNA sequences, hybrid DNA sequences and recombinant DNA molecules and the hosts transformed with them may be employed in the processes of this invention to produce streptavidin-like polypeptides and fused proteins.Type: GrantFiled: April 21, 1988Date of Patent: December 1, 1992Assignee: Biogen, Inc.Inventors: Harry M. Meade, Jeffrey L. Garwin
-
Patent number: 4950646Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human lipocortin-like polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human lipocortin-like polypeptide. In appropriate hosts these DNA sequences permit the production of human lipocortin-like polypeptides useful as anti-inflammatory agents and methods in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases as well as other disorders involving inflammatory processes.Type: GrantFiled: January 10, 1986Date of Patent: August 21, 1990Assignee: Biogen, Inc.Inventors: Barbara P. Wallner, R. Blake Pepinsky, Jeffrey L. Garwin, Daniel G. Schindler, Kuo-Sen Huang
-
Patent number: 4879224Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human phospholipase inhibitor polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human phospholipase inhibitor polypeptide. In appropiate hosts these DNA sequences permit the production of human phospholipase inhibitor polypeptides.Type: GrantFiled: January 10, 1985Date of Patent: November 7, 1989Assignee: Biogen, Inc.Inventors: Barbara P. Wallner, R. Blake Pepinsky, Jeffrey L. Garwin
-
Patent number: 4874743Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce human phospholipase inhibitor-like polypeptides and methods of making and using these products. The DNA sequences and recombinant DNA molecules are characterized in that they code on expression for a human phospholipase inhibitor-like polypeptide. In appropriate hosts these DNA sequences permit the production of human phospholipase inhibitor-like polypeptides useful as anti-inflammatory agents and methods in the treatment of arthritic, allergic, dermatologic, ophthalmic and collagen diseases as well as other disorders involving inflammatory processes.Type: GrantFiled: March 15, 1985Date of Patent: October 17, 1989Assignee: Biogen, Inc.Inventors: Barbara P. Wallner, R. Blake Pepinsky, Jeffrey L. Garwin